The nine valent human papillomavirus (HPV) vaccine (Escherichia coli) jointly developed by Xiamen University, Xiang'an Innovation Laboratory Xia Ningshao team, and Wantai Biotechnology was approved for market by the National Medical Products Administration at the end of May. Compared to the previously marketed bivalent vaccines, the 9-valent vaccine has increased protection against 5 high-risk HPV types and 2 low-risk HPV types that cause genital warts, increasing the prevention coverage of cervical cancer from approximately 80% achieved by the bivalent vaccine to 90%. ”Introduction by Zhang Jun, Dean of the School of Public Health at Xiamen University. This is the first domestically produced nine valent HPV vaccine in China, marking China as the second country after the United States to have the ability to independently supply high valent HPV vaccines. Zhang Jun stated that since 2019, this vaccine has conducted 5 clinical trials nationwide, involving over 11000 healthy volunteers aged 9 to 45, and has obtained solid research data. The development of the nine valent HPV vaccine began in 2007. During this period, the research team broke through the technical difficulties of expressing multiple types of HPV virus particles on the E. coli platform and was the first to develop the first domestically produced bivalent HPV vaccine with completely independent intellectual property rights in 2019. At present, this bivalent vaccine has been included in the free HPV vaccination program for eligible girls in many parts of the country, and has successfully obtained market access in 21 overseas countries, and has been selected for HPV vaccine immunization programs in 8 countries. Thanks to our independently developed engineering technology system for E. coli vaccines, the domestically produced nine valent vaccine has the characteristics of simple preparation and reasonable price, which will better help eliminate cervical cancer after being launched. ”Zhang Jun revealed that based on the team's E. coli vaccine engineering technology system, the team will continue to promote the development of the third generation of higher priced HPV vaccines, with the goal of covering all high-risk types of viruses and other virus types that cause precancerous lesions, further improving the preventive effect of HPV vaccines, and reducing public health screening costs. (New Society)